{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:06:26Z","timestamp":1792479986326,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jogc.2025.103060","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T16:00:13Z","timestamp":1753459213000},"page":"103060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Technical Update No. 462: Abnormal maternal serum markers and adverse pregnancy outcomes"],"prefix":"10.1016","volume":"47","author":[{"given":"Amir","family":"Aviram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Mei-Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Cassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Figueiro-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bujold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.semperi.2015.11.003","article-title":"Development of prenatal screening\u2014A historical overview","volume":"40","author":"Cuckle","year":"2016","journal-title":"Semin Perinatol"},{"issue":"7","key":"10.1016\/j.jogc.2025.103060_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pd.4597","article-title":"First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-\u03b2 human chorionic gonadotrophin, placental growth factor, and \u03b1-fetoprotein","volume":"35","author":"Huang","year":"2015","journal-title":"Prenat Diagn"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000341264","article-title":"Competing risks model in early screening for preeclampsia by biophysical and biochemical markers","volume":"33","author":"Akolekar","year":"2013","journal-title":"Fetal Diagn Ther"},{"issue":"7","key":"10.1016\/j.jogc.2025.103060_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.jogc.2025.103060_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1701-2163(16)32973-5","article-title":"Obstetrical Complications Associated With Abnormal Maternal Serum Markers Analytes","volume":"30","author":"Gagnon","year":"2008","journal-title":"Journal of Obstetrics and Gynaecology Canada"},{"issue":"10","key":"10.1016\/j.jogc.2025.103060_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jogc.2023.05.022","article-title":"Guideline No. 442: Fetal Growth Restriction: Screening, Diagnosis, and Management in Singleton Pregnancies","volume":"45","author":"Kingdom","year":"2023","journal-title":"Journal of Obstetrics and Gynaecology Canada"},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jogc.2022.03.002","article-title":"Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management","volume":"44","author":"Magee","year":"2022","journal-title":"Journal of Obstetrics and Gynaecology Canada"},{"key":"10.1016\/j.jogc.2025.103060_bib8","series-title":"No. 348-Joint SOGC-CCMG Guideline: Update on Prenatal Screening for Fetal Aneuploidy, Fetal Anomalies, and Adverse Pregnancy Outcomes","author":"Audibert","year":"2017"},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib9","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/AOG.0b013e3181da93da","article-title":"First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes","volume":"115","author":"Dugoff","year":"2010","journal-title":"Obstetrics and gynecology"},{"key":"10.1016\/j.jogc.2025.103060_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2393-8-33","article-title":"Serum screening with Down\u2019s syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis","volume":"8","author":"Morris","year":"2008","journal-title":"BMC Pregnancy Childbirth"},{"issue":"4","key":"10.1016\/j.jogc.2025.103060_bib20","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ajog.2004.06.052","article-title":"First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER Trial)","volume":"191","author":"Dugoff","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogc.2025.103060_bib49","article-title":"First-Trimester PLGF and PAPP-A and the Risk of Placenta-Mediated Complications: PREDICTION Prospective Study","author":"C\u00f4t\u00e9","year":"2024","journal-title":"Journal of Obstetrics and Gynaecology Canada"},{"issue":"4","key":"10.1016\/j.jogc.2025.103060_bib50","doi-asserted-by":"crossref","first-page":"E369","DOI":"10.1055\/s-0040-1716741","article-title":"Adverse Pregnancy Outcomes by Degree of Maternal Serum Analyte Elevation: A Retrospective Cohort Study","volume":"10","author":"Yeaton-Massey","year":"2020","journal-title":"AJP Rep"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib53","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/01.AOG.0000172419.37410.eb","article-title":"Quad screen as a predictor of adverse pregnancy outcome","volume":"106","author":"Dugoff","year":"2005","journal-title":"Obstetrics and gynecology"},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/pd.2505","article-title":"Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome","volume":"30","author":"Huang","year":"2010","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jogc.2025.103060_bib62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preghy.2023.11.003","article-title":"Association between human chorionic gonadotropin (hCG) levels and adverse pregnancy outcomes: A systematic review and meta-analysis","volume":"34","author":"Skogler","year":"2023","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.jogc.2025.103060_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-800094-6.00005-4","article-title":"Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia","volume":"63","author":"Kalousov\u00e1","year":"2014","journal-title":"Adv Clin Chem"},{"issue":"3","key":"10.1016\/j.jogc.2025.103060_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/uog.22093","article-title":"Screening for pre-eclampsia at 11-13 weeks\u2019 gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both","volume":"56","author":"Mazer Zumaeta","year":"2020","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/uog.3809","article-title":"First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death","volume":"28","author":"Spencer","year":"2006","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.jogc.2025.103060_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/uog.15849","article-title":"Maternal serum PAPP-A and free \u03b2-hCG at 12, 22 and 32 weeks\u2019 gestation in screening for pre-eclampsia","volume":"47","author":"Wright","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pd.1890","article-title":"Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia","volume":"28","author":"Spencer","year":"2008","journal-title":"Prenat Diagn"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/uog.5163","article-title":"First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery","volume":"31","author":"Spencer","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.jogc.2025.103060_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00404-020-05960-1","article-title":"First trimester serum PAPP-A is associated with placenta accreta: a retrospective study","volume":"303","author":"Wang","year":"2021","journal-title":"Arch Gynecol Obstet"},{"issue":"47","key":"10.1016\/j.jogc.2025.103060_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034473","article-title":"Meta-analysis for the relationship between circulating pregnancy-associated plasma protein A and placenta accreta spectrum","volume":"102","author":"Li","year":"2023","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/uog.5165","article-title":"First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses","volume":"31","author":"Spencer","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jogc.2025.103060_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1515\/jpm-2022-0241","article-title":"First trimester low maternal serum pregnancy associated plasma protein-A (PAPP-A) as a screening method for adverse pregnancy outcomes","volume":"51","author":"Kantomaa","year":"2022","journal-title":"J Perinat Med"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1083\/jcb.93.1.190","article-title":"Cytological localization of chorionic gonadotropin alpha and placental lactogen mRNAs during development of the human placenta","volume":"93","author":"Hoshina","year":"1982","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jogc.2025.103060_bib23","series-title":"American Journal of Obstetrics and Gynecology","first-page":"1452","article-title":"Association of extreme first-trimester free human chorionic gonadotropin-\u03b2, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes","volume":"191","author":"Krantz","year":"2004"},{"issue":"6","key":"10.1016\/j.jogc.2025.103060_bib24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1471-0528.17691","article-title":"Association between adverse pregnancy outcome and placental biomarkers in the first trimester: A prospective cohort study","volume":"131","author":"Sovio","year":"2024","journal-title":"BJOG"},{"issue":"2S","key":"10.1016\/j.jogc.2025.103060_bib25","doi-asserted-by":"crossref","first-page":"S725","DOI":"10.1016\/j.ajog.2017.12.002","article-title":"Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers","volume":"218","author":"Gaccioli","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.jogc.2025.103060_bib26","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/HYPERTENSIONAHA.123.21568","article-title":"Maternal First-Trimester Alpha-Fetoprotein and Placenta-Mediated Pregnancy Complications","volume":"80","author":"Melamed","year":"2023","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.jogc.2025.103060_bib27","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1210\/jcem.87.4.8430","article-title":"Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jogc.2025.103060_bib28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejogrb.2014.09.027","article-title":"Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis","volume":"182","author":"Allen","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/pd.4087","article-title":"Maternal serum placental growth factor and \u03b1-fetoprotein testing in first trimester screening for Down syndrome","volume":"33","author":"Donalson","year":"2013","journal-title":"Prenat Diagn"},{"issue":"11","key":"10.1016\/j.jogc.2025.103060_bib30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/pd.4194","article-title":"First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA","volume":"33","author":"Johnson","year":"2013","journal-title":"Prenat Diagn"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000357430","article-title":"First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical Testing","volume":"35","author":"Wright","year":"2014","journal-title":"Fetal Diagn Ther"},{"issue":"8","key":"10.1016\/j.jogc.2025.103060_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/pd.4609","article-title":"Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures","volume":"35","author":"Palomaki","year":"2015","journal-title":"Prenat Diagn"},{"issue":"8","key":"10.1016\/j.jogc.2025.103060_bib33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/pd.5090","article-title":"Expanded conventional first trimester screening","volume":"37","author":"Carmichael","year":"2017","journal-title":"Prenat Diagn"},{"issue":"4","key":"10.1016\/j.jogc.2025.103060_bib34","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/uog.15818","article-title":"Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks\u2019 gestation in screening for pre-eclampsia","volume":"47","author":"Bredaki","year":"2016","journal-title":"Ultrasound in Obstetrics & Gynecology"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12884-020-2789-2","article-title":"First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases","volume":"20","author":"Hu","year":"2020","journal-title":"BMC Pregnancy Childbirth"},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib36","doi-asserted-by":"crossref","first-page":"499.e1","DOI":"10.1016\/j.ajog.2019.11.1264","article-title":"First-trimester maternal serum alpha fetoprotein is associated with ischemic placental disease","volume":"222","author":"Dinglas","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib37","doi-asserted-by":"crossref","first-page":"126.e1","DOI":"10.1016\/j.ajog.2017.10.024","article-title":"First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume","volume":"218","author":"Sonek","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.jogc.2025.103060_bib38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/HYPERTENSIONAHA.121.17267","article-title":"Induction of the PPAR\u03b3 (Peroxisome Proliferator-Activated Receptor \u03b3)-GCM1 (Glial Cell Missing 1) Syncytialization Axis Reduces sFLT1 (Soluble fms-Like Tyrosine Kinase 1) in the Preeclamptic Placenta","volume":"78","author":"Armistead","year":"2021","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.jogc.2025.103060_bib40","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/HYPERTENSIONAHA.121.17047","article-title":"PlGF (Placental Growth Factor) Testing in Clinical Practice: Evidence From a Canadian Tertiary Maternity Referral Center","volume":"77","author":"McLaughlin","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib41","doi-asserted-by":"crossref","first-page":"62.e1","DOI":"10.1016\/j.ajog.2015.02.018","article-title":"Competing risks model in screening for preeclampsia by maternal characteristics and medical history","volume":"213","author":"Wright","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.jogc.2025.103060_bib42","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/uog.6244","article-title":"Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia","volume":"32","author":"Akolekar","year":"2008","journal-title":"Ultrasound in Obstetrics and Gynecology"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/uog.19112","article-title":"Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks\u2019 gestation","volume":"52","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000321694","article-title":"Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks","volume":"29","author":"Karagiannis","year":"2011","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.jogc.2025.103060_bib46","unstructured":"Risk for fetal growth restriction. The Fetal Medicine Foundation."},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.119.13360","article-title":"Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women: A Systematic Review and Meta-Analysis","volume":"74","author":"Agrawal","year":"2019","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.jogc.2025.103060_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/pd.1970140316","article-title":"Prenatal detection of X-linked ichthyosis by maternal serum screening for Down syndrome","volume":"14","author":"Bartels","year":"1994","journal-title":"Prenat Diagn"},{"issue":"9061","key":"10.1016\/j.jogc.2025.103060_bib52","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(96)09264-1","article-title":"Activin A and inhibin A as possible endocrine markers for preeclampsia","volume":"349","author":"Muttukrishna","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jogc.2025.103060_bib54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/AOG.0000000000001889","article-title":"First-Trimester and Second-Trimester Maternal Serum Biomarkers as Predictors of Placental Abruption","volume":"129","author":"Ananth","year":"2017","journal-title":"Obstetrics and gynecology"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/pd.4281","article-title":"Prediction of obstetrical risk using maternal serum markers and clinical risk factors","volume":"34","author":"Metcalfe","year":"2014","journal-title":"Prenat Diagn"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.AOG.0000191302.79560.d8","article-title":"Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome","volume":"107","author":"Smith","year":"2006","journal-title":"Obstetrics and Gynecology"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib57","first-page":"277","article-title":"Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome","volume":"97","author":"Krause","year":"2001","journal-title":"Obstetrics and Gynecology"},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib58","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/0029-7844(96)00310-9","article-title":"The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications","volume":"88","author":"Waller","year":"1996","journal-title":"Obstetrics and Gynecology"},{"issue":"3","key":"10.1016\/j.jogc.2025.103060_bib59","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1701-2163(16)32756-6","article-title":"Ultrasound detection of placental insufficiency in women with elevated second trimester serum alpha-fetoprotein or human chorionic gonadotropin","volume":"30","author":"Toal","year":"2008","journal-title":"J Obstet Gynaecol Can"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0029-7844(95)00377-0","article-title":"Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein","volume":"87","author":"KD","year":"1996","journal-title":"Obstetrics and gynecology"},{"issue":"2","key":"10.1016\/j.jogc.2025.103060_bib71","doi-asserted-by":"crossref","first-page":"S1145","DOI":"10.1016\/j.ajog.2021.08.027","article-title":"Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction","volume":"226","author":"McLaughlin","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jogc.2025.103060_bib72","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000514378","article-title":"Gestational Age-Specific Reference Ranges for the sFlt-1\/PlGF Immunoassay Ratio in Twin Pregnancies","volume":"48","author":"De La Calle","year":"2021","journal-title":"Fetal Diagn Ther"},{"issue":"5","key":"10.1016\/j.jogc.2025.103060_bib63","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajog.2017.12.238","article-title":"Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage","volume":"218","author":"Roberge","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogc.2025.103060_bib64","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1161\/HYPERTENSIONAHA.123.22584","article-title":"Hypertension Prospective Validation of First-Trimester Screening for Preterm Preeclampsia in Nulliparous Women (PREDICTION Study)","volume":"81","author":"Bujold","year":"2024","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jogc.2025.103060_bib67","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/AOG.0000000000002708","article-title":"ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy","volume":"132","year":"2018","journal-title":"Obstetrics & Gynecology"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216325003068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216325003068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:33:19Z","timestamp":1766154799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216325003068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1701216325003068"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2025.103060","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Technical Update No. 462: Abnormal maternal serum markers and adverse pregnancy outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2025.103060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103060"}}